Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of finerenone plus empagliflozin versus either drug alone in chronic kidney disease and type 2 diabetes
MOH_2022-04-25_010749Phase 2Not yet recruiting
- Sponsor
- Bayer
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) comparing Finerenone + empagliflozin, Finerenone + placebo and Empagliflozin + placebo (3 arms). Primary endpoint: Urinary albumin-to-creatinine ratio. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
finerenoneempagliflozin
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2022-04-25_010749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-25_010749.